• Novozymes posted 8% organic sales growth in H1 2026, including a ~1.5 percentage-point drag from exiting certain countries.
• Adjusted EBITDA margin edged up 30 basis points year-on-year to 37.7%, despite a currency headwind.
• Adjusted net profit excluding PPA rose 8% from a year earlier.
• Free cash flow before acquisitions came in at 14% of sales; NIBD/EBITDA was 1.8x, with CAPEX at 9.7% of sales.
• Raised 2026 organic sales growth outlook to 7%-8%; expects adjusted EBITDA margin at the higher end of 37%-38%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novozymes A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608191141OMX_____CNEWS_EN_GNW1001258382_en) on August 19, 2026, and is solely responsible for the information contained therein.